�ݺ�ߣshows by User: MayuriJagtap3

�ݺ�ߣshows by User: MayuriJagtap3 / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: MayuriJagtap3 / Thu, 17 Feb 2022 08:52:01 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: MayuriJagtap3 Neuroprotective effects of α-Lipoic acid alone and in combination with ferulic acid in diabetic neuropathy induced rats /slideshow/neuroprotective-effects-of-lipoic-acid-alone-and-in-combination-with-ferulic-acid-in-diabetic-neuropathy-induced-rats/251192206 ideationppt-220217085201
The present pre-clinical activity was undertaken to screen the two antioxidants, mainly α-lipoic acid and ferulic acid alone, and in combination in neuropathic pain induced by diabetes in rats. The activity was confirmed by assessing various behavioral as well as biochemical and histopathological studies. The study was performed on adult albino rats. The rats were divided into different groups, and each group contained six rats. Diabetic neuropathy in rats was induced by administering a freshly prepared single dose of streptozotocin (60 mg/kg, i.p). After development of neuropathy the rats were treated with α-lipoic acid (25 mg/kg/day, p.o), ferulic acid (10 mg/kg/day, p.o) and standard drug Pregabalin (30 mg/kg/day i.p). One group received the combination of antioxidants, i.e.,α-lipoic acid (12mg/kg, p.o) and ferulic acid (05 mg/kg/day, p.o) respectively, for two weeks. Neuropathic pain was assessed using mechanical allodynia, mechanical hyperalgesia, cold allodynia, and thermal allodynia. Biochemical parameters of blood glucose, nitric oxide, level of lipid peroxidase, reduced glutathione, and membrane-bound ATPases activities were also studied. Neuropathic pain induced rats showed a significant alteration in behavioral and biochemical parameters. Treatment with α-lipoic acid in combination with Ferulic acid significantly restored the altered parameters towards normal as compared to single antioxidants, thus provided proper neuroprotection. This effect might be due to the strong free radical scavenging potential of α-lipoic acid and ferulic acid.]]>
The present pre-clinical activity was undertaken to screen the two antioxidants, mainly α-lipoic acid and ferulic acid alone, and in combination in neuropathic pain induced by diabetes in rats. The activity was confirmed by assessing various behavioral as well as biochemical and histopathological studies. The study was performed on adult albino rats. The rats were divided into different groups, and each group contained six rats. Diabetic neuropathy in rats was induced by administering a freshly prepared single dose of streptozotocin (60 mg/kg, i.p). After development of neuropathy the rats were treated with α-lipoic acid (25 mg/kg/day, p.o), ferulic acid (10 mg/kg/day, p.o) and standard drug Pregabalin (30 mg/kg/day i.p). One group received the combination of antioxidants, i.e.,α-lipoic acid (12mg/kg, p.o) and ferulic acid (05 mg/kg/day, p.o) respectively, for two weeks. Neuropathic pain was assessed using mechanical allodynia, mechanical hyperalgesia, cold allodynia, and thermal allodynia. Biochemical parameters of blood glucose, nitric oxide, level of lipid peroxidase, reduced glutathione, and membrane-bound ATPases activities were also studied. Neuropathic pain induced rats showed a significant alteration in behavioral and biochemical parameters. Treatment with α-lipoic acid in combination with Ferulic acid significantly restored the altered parameters towards normal as compared to single antioxidants, thus provided proper neuroprotection. This effect might be due to the strong free radical scavenging potential of α-lipoic acid and ferulic acid.]]> Thu, 17 Feb 2022 08:52:01 GMT /slideshow/neuroprotective-effects-of-lipoic-acid-alone-and-in-combination-with-ferulic-acid-in-diabetic-neuropathy-induced-rats/251192206 MayuriJagtap3@slideshare.net(MayuriJagtap3) Neuroprotective effects of α-Lipoic acid alone and in combination with ferulic acid in diabetic neuropathy induced rats MayuriJagtap3 The present pre-clinical activity was undertaken to screen the two antioxidants, mainly α-lipoic acid and ferulic acid alone, and in combination in neuropathic pain induced by diabetes in rats. The activity was confirmed by assessing various behavioral as well as biochemical and histopathological studies. The study was performed on adult albino rats. The rats were divided into different groups, and each group contained six rats. Diabetic neuropathy in rats was induced by administering a freshly prepared single dose of streptozotocin (60 mg/kg, i.p). After development of neuropathy the rats were treated with α-lipoic acid (25 mg/kg/day, p.o), ferulic acid (10 mg/kg/day, p.o) and standard drug Pregabalin (30 mg/kg/day i.p). One group received the combination of antioxidants, i.e.,α-lipoic acid (12mg/kg, p.o) and ferulic acid (05 mg/kg/day, p.o) respectively, for two weeks. Neuropathic pain was assessed using mechanical allodynia, mechanical hyperalgesia, cold allodynia, and thermal allodynia. Biochemical parameters of blood glucose, nitric oxide, level of lipid peroxidase, reduced glutathione, and membrane-bound ATPases activities were also studied. Neuropathic pain induced rats showed a significant alteration in behavioral and biochemical parameters. Treatment with α-lipoic acid in combination with Ferulic acid significantly restored the altered parameters towards normal as compared to single antioxidants, thus provided proper neuroprotection. This effect might be due to the strong free radical scavenging potential of α-lipoic acid and ferulic acid. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ideationppt-220217085201-thumbnail.jpg?width=120&height=120&fit=bounds" /> The present pre-clinical activity was undertaken to screen the two antioxidants, mainly α-lipoic acid and ferulic acid alone, and in combination in neuropathic pain induced by diabetes in rats. The activity was confirmed by assessing various behavioral as well as biochemical and histopathological studies. The study was performed on adult albino rats. The rats were divided into different groups, and each group contained six rats. Diabetic neuropathy in rats was induced by administering a freshly prepared single dose of streptozotocin (60 mg/kg, i.p). After development of neuropathy the rats were treated with α-lipoic acid (25 mg/kg/day, p.o), ferulic acid (10 mg/kg/day, p.o) and standard drug Pregabalin (30 mg/kg/day i.p). One group received the combination of antioxidants, i.e.,α-lipoic acid (12mg/kg, p.o) and ferulic acid (05 mg/kg/day, p.o) respectively, for two weeks. Neuropathic pain was assessed using mechanical allodynia, mechanical hyperalgesia, cold allodynia, and thermal allodynia. Biochemical parameters of blood glucose, nitric oxide, level of lipid peroxidase, reduced glutathione, and membrane-bound ATPases activities were also studied. Neuropathic pain induced rats showed a significant alteration in behavioral and biochemical parameters. Treatment with α-lipoic acid in combination with Ferulic acid significantly restored the altered parameters towards normal as compared to single antioxidants, thus provided proper neuroprotection. This effect might be due to the strong free radical scavenging potential of α-lipoic acid and ferulic acid.

Neuroprotective effects of 留-Lipoic acid alone and in combination with ferulic acid in diabetic neuropathy induced rats from Mayuri N Jagtap

]]> 105 0 https://cdn.slidesharecdn.com/ss_thumbnails/ideationppt-220217085201-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Cell Free Fetal DNA Non Inavasive Prenatal Diagnostic Methods and Applications /slideshow/cell-free-fetal-dna-non-inavasive-prenatal-diagnostic-methods-and-applications/251168994 cellfreefetaldnanon-inavasiveprenataldiagnosticmethodsandapplications-220214101538
Noninvasive prenatal testing (NIPT) has become possible to identify cell free fetal DNA (cffDNA) in maternal bloodstream. The effective implementation of noninvasive testing into a clinical practice such as fetal sex detection, RhD genotyping and fetal chromosomal aneuploidy detection have been enabled by the technical advances in molecular analysis of fetal DNA (e.g., digital polymerase chain reaction (PCR) and massively parallel sequencing (MPS) in early years. cffDNA technology has significant superiority as difference compared to routine serum sample screening by means of it has high accuracy and sensitivity. Though, cffDNA positive results still need validation by the invasive testing. The main purpose of cell free fetal DNA is to become first priority of NIPT option only due to its high accuracy rate and its safety. The ultimate goal is to develop the reliable method which could eventually swap invasive prenatal testing procedures. In maternal circulation with relatively high concentration the analysis of cell-free fetal DNA in plasma is one of the innovative non-invasive prenatal testing options. Recently Commercial tests for cell-free fetal DNA in maternal blood have become available. This review briefly summarizes the technical aspects of the noninvasive prenatal testing along with analysis of cffDNA and application of it in clinical practice.]]>
Noninvasive prenatal testing (NIPT) has become possible to identify cell free fetal DNA (cffDNA) in maternal bloodstream. The effective implementation of noninvasive testing into a clinical practice such as fetal sex detection, RhD genotyping and fetal chromosomal aneuploidy detection have been enabled by the technical advances in molecular analysis of fetal DNA (e.g., digital polymerase chain reaction (PCR) and massively parallel sequencing (MPS) in early years. cffDNA technology has significant superiority as difference compared to routine serum sample screening by means of it has high accuracy and sensitivity. Though, cffDNA positive results still need validation by the invasive testing. The main purpose of cell free fetal DNA is to become first priority of NIPT option only due to its high accuracy rate and its safety. The ultimate goal is to develop the reliable method which could eventually swap invasive prenatal testing procedures. In maternal circulation with relatively high concentration the analysis of cell-free fetal DNA in plasma is one of the innovative non-invasive prenatal testing options. Recently Commercial tests for cell-free fetal DNA in maternal blood have become available. This review briefly summarizes the technical aspects of the noninvasive prenatal testing along with analysis of cffDNA and application of it in clinical practice.]]> Mon, 14 Feb 2022 10:15:38 GMT /slideshow/cell-free-fetal-dna-non-inavasive-prenatal-diagnostic-methods-and-applications/251168994 MayuriJagtap3@slideshare.net(MayuriJagtap3) Cell Free Fetal DNA Non Inavasive Prenatal Diagnostic Methods and Applications MayuriJagtap3 Noninvasive prenatal testing (NIPT) has become possible to identify cell free fetal DNA (cffDNA) in maternal bloodstream. The effective implementation of noninvasive testing into a clinical practice such as fetal sex detection, RhD genotyping and fetal chromosomal aneuploidy detection have been enabled by the technical advances in molecular analysis of fetal DNA (e.g., digital polymerase chain reaction (PCR) and massively parallel sequencing (MPS) in early years. cffDNA technology has significant superiority as difference compared to routine serum sample screening by means of it has high accuracy and sensitivity. Though, cffDNA positive results still need validation by the invasive testing. The main purpose of cell free fetal DNA is to become first priority of NIPT option only due to its high accuracy rate and its safety. The ultimate goal is to develop the reliable method which could eventually swap invasive prenatal testing procedures. In maternal circulation with relatively high concentration the analysis of cell-free fetal DNA in plasma is one of the innovative non-invasive prenatal testing options. Recently Commercial tests for cell-free fetal DNA in maternal blood have become available. This review briefly summarizes the technical aspects of the noninvasive prenatal testing along with analysis of cffDNA and application of it in clinical practice. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cellfreefetaldnanon-inavasiveprenataldiagnosticmethodsandapplications-220214101538-thumbnail.jpg?width=120&height=120&fit=bounds" /> Noninvasive prenatal testing (NIPT) has become possible to identify cell free fetal DNA (cffDNA) in maternal bloodstream. The effective implementation of noninvasive testing into a clinical practice such as fetal sex detection, RhD genotyping and fetal chromosomal aneuploidy detection have been enabled by the technical advances in molecular analysis of fetal DNA (e.g., digital polymerase chain reaction (PCR) and massively parallel sequencing (MPS) in early years. cffDNA technology has significant superiority as difference compared to routine serum sample screening by means of it has high accuracy and sensitivity. Though, cffDNA positive results still need validation by the invasive testing. The main purpose of cell free fetal DNA is to become first priority of NIPT option only due to its high accuracy rate and its safety. The ultimate goal is to develop the reliable method which could eventually swap invasive prenatal testing procedures. In maternal circulation with relatively high concentration the analysis of cell-free fetal DNA in plasma is one of the innovative non-invasive prenatal testing options. Recently Commercial tests for cell-free fetal DNA in maternal blood have become available. This review briefly summarizes the technical aspects of the noninvasive prenatal testing along with analysis of cffDNA and application of it in clinical practice.

Cell Free Fetal DNA Non Inavasive Prenatal Diagnostic Methods and Applications from Mayuri N Jagtap

]]> 121 0 https://cdn.slidesharecdn.com/ss_thumbnails/cellfreefetaldnanon-inavasiveprenataldiagnosticmethodsandapplications-220214101538-thumbnail.jpg?width=120&height=120&fit=bounds presentation 000000 http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Small Volume Parenterals /slideshow/small-volume-parenterals-240530895/240530895 sterileproductmayu-201224071624
Small Volume Parenterals]]>
Small Volume Parenterals]]> Thu, 24 Dec 2020 07:16:24 GMT /slideshow/small-volume-parenterals-240530895/240530895 MayuriJagtap3@slideshare.net(MayuriJagtap3) Small Volume Parenterals MayuriJagtap3 Small Volume Parenterals <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/sterileproductmayu-201224071624-thumbnail.jpg?width=120&height=120&fit=bounds" /> Small Volume Parenterals

Small Volume Parenterals from Mayuri N Jagtap

]]> 39 0 https://cdn.slidesharecdn.com/ss_thumbnails/sterileproductmayu-201224071624-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Cosmeceuticals /slideshow/cosmeceuticals-240530490/240530490 cosmeceuticals-201224070934
A cosmetic that has or is claimed to have medicinal properties.]]>
A cosmetic that has or is claimed to have medicinal properties.]]> Thu, 24 Dec 2020 07:09:33 GMT /slideshow/cosmeceuticals-240530490/240530490 MayuriJagtap3@slideshare.net(MayuriJagtap3) Cosmeceuticals MayuriJagtap3 A cosmetic that has or is claimed to have medicinal properties. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cosmeceuticals-201224070934-thumbnail.jpg?width=120&height=120&fit=bounds" /> A cosmetic that has or is claimed to have medicinal properties.

Cosmeceuticals from Mayuri N Jagtap

]]> 99 0 https://cdn.slidesharecdn.com/ss_thumbnails/cosmeceuticals-201224070934-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Compartment models- Assessment of Pharmacokinetic Parameters from Plasma and Urine data /slideshow/compartment-models-assessment-of-pharmacokinetic-parameters-from-plasma-and-urine-data/238976376 bcdd-201026122611
Assessment of Pharmacokinetic Parameters from Plasma and Urine data:- I.V. Injection with loading dose & Assessment of pharmacokinetic parameters. ]]>
Assessment of Pharmacokinetic Parameters from Plasma and Urine data:- I.V. Injection with loading dose & Assessment of pharmacokinetic parameters. ]]> Mon, 26 Oct 2020 12:26:11 GMT /slideshow/compartment-models-assessment-of-pharmacokinetic-parameters-from-plasma-and-urine-data/238976376 MayuriJagtap3@slideshare.net(MayuriJagtap3) Compartment models- Assessment of Pharmacokinetic Parameters from Plasma and Urine data MayuriJagtap3 Assessment of Pharmacokinetic Parameters from Plasma and Urine data:- I.V. Injection with loading dose & Assessment of pharmacokinetic parameters. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bcdd-201026122611-thumbnail.jpg?width=120&height=120&fit=bounds" /> Assessment of Pharmacokinetic Parameters from Plasma and Urine data:- I.V. Injection with loading dose & Assessment of pharmacokinetic parameters.

Compartment models- Assessment of Pharmacokinetic Parameters from Plasma and Urine data from Mayuri N Jagtap

]]> 182 0 https://cdn.slidesharecdn.com/ss_thumbnails/bcdd-201026122611-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://public.slidesharecdn.com/v2/images/profile-picture.png https://cdn.slidesharecdn.com/ss_thumbnails/ideationppt-220217085201-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/neuroprotective-effects-of-lipoic-acid-alone-and-in-combination-with-ferulic-acid-in-diabetic-neuropathy-induced-rats/251192206 Neuroprotective effect... https://cdn.slidesharecdn.com/ss_thumbnails/cellfreefetaldnanon-inavasiveprenataldiagnosticmethodsandapplications-220214101538-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/cell-free-fetal-dna-non-inavasive-prenatal-diagnostic-methods-and-applications/251168994 Cell Free Fetal DNA No... https://cdn.slidesharecdn.com/ss_thumbnails/sterileproductmayu-201224071624-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/small-volume-parenterals-240530895/240530895 Small Volume Parenterals